Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379

Raw json | Download

{
  "resourceType" : "Evidence",
  "id" : "267238",
  "meta" : {
    "versionId" : "9",
    "lastUpdated" : "2025-12-11T20:35:21.032Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 267238</b></p><a name=\"267238\"> </a><a name=\"hc267238\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 9; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Evidence/267238\">https://fevir.net/resources/Evidence/267238</a></p><p><b>identifier</b>: FEvIR Object Identifier/267238, FEvIR Linking Identifier/NCT03421379-secondaryOutcomeMeasure-2--OG000</p><p><b>name</b>: NCT03421379_secondaryOutcomeMeasure_2_OG000</p><p><b>title</b>: Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379</p><p><b>citeAs</b>: </p><div><p>Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267238. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267238. Computable resource at: https://fevir.net/resources/Evidence/267238#json.</p>\n</div><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>note</b>: , </p><blockquote><div><p>Outcome Measure Population Description: All randomized participants who received at least one dose of study drug and had evaluable PK data.</p>\n</div></blockquote><blockquote><div><p>Outcome Measure Denominator Units: Participants</p>\n</div></blockquote><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG000)</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-267229.html\">Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration -  (NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000396}\">geometric mean</span></p><p><b>quantity</b>: 4830 Picogram*hour/milliliter (pg*h/mL)</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table><h3>AttributeEstimates</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Geometric Coefficient of Variation</span></td><td>89 Picogram*hour/milliliter (pg*h/mL)</td></tr></table></blockquote></div>"
  },
  "url" : "https://fevir.net/resources/Evidence/267238",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net/FOI",
      "value" : "267238",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    },
    {
      "type" : {
        "text" : "FEvIR Linking Identifier"
      },
      "system" : "https://fevir.net/FLI",
      "value" : "NCT03421379-secondaryOutcomeMeasure-2--OG000",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "name" : "NCT03421379_secondaryOutcomeMeasure_2_OG000",
  "title" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379",
  "citeAs" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267238. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267238. Computable resource at: https://fevir.net/resources/Evidence/267238#json.",
  "status" : "active",
  "author" : [
    {
      "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
    }
  ],
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "variableDefinition" : [
    {
      "description" : "Glucagon Nasal Powder",
      "note" : [
        {
          "text" : "Outcome Measure Population Description: All randomized participants who received at least one dose of study drug and had evaluable PK data."
        },
        {
          "text" : "Outcome Measure Denominator Units: Participants"
        }
      ],
      "variableRole" : "population",
      "observed" : {
        "identifier" : {
          "type" : {
            "text" : "ClinicalTrials.gov Outcome Measurement Group Id"
          },
          "value" : "OG000"
        },
        "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
      }
    },
    {
      "variableRole" : "outcome",
      "observed" : {
        🔗 "reference" : "EvidenceVariable/267229",
        "type" : "EvidenceVariable",
        "identifier" : {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "NCT03421379-secondaryOutcome-2",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        },
        "display" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration -  (NCT03421379)"
      }
    }
  ],
  "statistic" : [
    {
      "statisticType" : {
        "coding" : [
          {
            "system" : "https://fevir.net/sevco",
            "code" : "STATO:0000396",
            "display" : "geometric mean"
          }
        ]
      },
      "quantity" : {
        "value" : 4830,
        "unit" : "Picogram*hour/milliliter (pg*h/mL)"
      },
      "sampleSize" : {
        "knownDataCount" : 71
      },
      "attributeEstimate" : [
        {
          "type" : {
            "text" : "Geometric Coefficient of Variation"
          },
          "quantity" : {
            "value" : 89,
            "unit" : "Picogram*hour/milliliter (pg*h/mL)"
          }
        }
      ]
    }
  ]
}